Pfizer publishes on successful use of EpiSwitch biomarkers evaluating tumour status and treatment outcomes from the JAVELIN Bladder 100 Trial
Pfizer publishes on successful use of EpiSwitch biomarkers evaluating tumour status and treatment outcomes from the JAVELIN Bladder 100 Trial
Issued US reimbursement code for Checkpoint Inhibitor Response Test (EpiSwitch® CiRT)
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.